Infections transmitted from donors to recipients following organ transplantation

National Medical Journal of India

Volumn 18, Issue 4, 2005, Pages 189-194

  Rao, Yannam Govardhana ^a   Mirza, Darius F ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; CYCLOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; LYMPHOCYTE ANTIBODY; PENICILLIN G; RIBAVIRIN; TACROLIMUS; TENOFOVIR;

BACTERIAL INFECTION; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; DONOR; DYING; EPSTEIN BARR VIRUS; GRAFT REJECTION; HEART BEAT; HEMODYNAMICS; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE DEFICIENCY; INFECTION RISK; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PARASITOSIS; PENICILLIN ALLERGY; POSTOPERATIVE INFECTION; RECIPIENT; REVIEW; SYPHILIS; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS INFECTION;

BACTERIAL INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PARASITIC DISEASES; VIRUS DISEASES;

EID: 26844489001     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Eastlund T. Infectious disease transmission through cell, tissue, and organ transplantation: Reducing the risk through donor selection. Cell Transplant 1995;4:455-77.
2. Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis 2001;33 (Suppl 1):S9-S14.
3. Terrault NA, Wright TL. Viral hepatitis A through G. In: Feldman M, Scharschmidt BF, Sleisenger MH (eds). Sleisenger & Fordtran's: Gastrointestinal and liver disease. 6th ed. Philadelphia:W.B. Saunders; 1998.
4. Lutwick LI, Sywassink JM, Corry RJ, Shorey JW. The transmission of hepatitis B by renal transplantation. Clin Nephrol 1983;19:317-19.
5. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979;91:412-13.
6. Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994;58:114-16.
7. Chan PC, Lok AS, Cheng IK, Chan MK. The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients. Transplantation 1992;53:128-31.
8. Liang TJ, Baruch Y, Ben-Porath E, Enat R, Bassan L, Brown NV, et al. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 1991;13:1044-51.
9. Liang TJ, Bodenheimer HC Jr, Yankee R, Brown NV, Chang K, Huang J, et al. Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification. J Med Virol 1994;42:151-7.
10. Dodson SF, Issa S, Araya V, Gayowski T, Pinna. A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:1582-4.
11. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-74.
12. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995;59:230-4.
13. Kadian M, Hawkins K, Schwartz H, Miller C. Use of hepatitis B core antibody-positive multi-organ donors. J Transplant Coord 1994;4:57.
14. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997;3:105-11.
15. McGory R, Ishitani M, Oliveira W, Stevenson W, McCullough C, Pruett T. Hepatitis B immune globulin dose requirements following orthotopic liver transplantation for chronic hepatitis B cirrhosis. Transplant Proc 1996;28:1687-8.
16. Castells L, Vargas V, Rodriguez F, Allende H, Buti M, Sanchez-Avila JF, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002;8:892-900.
17. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-13.
18. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: Long-term results. Am J Transplant 2003;3:999-1002.
19. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058-61.
20. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-65S.
21. Pereira BJ, Wright TL, Schmid CH, Bryan CF, Cheung RC, Cooper ES, et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: A US National Collaborative Study. Kidney Int 1994;46:886-92.
22. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40.
23. Mulligan DC, Goldstein RM, Crippin JS, Abouljoud MS, Levy MF, Husberg BS, et al. Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplant Proc 1995;27:1204-5.
24. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-93; discussion 393-4.
25. Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002;73:582-7.
26. Laskus T, Wang LF, Rakela J, Vargas H, Pinna AD, Tsamandas AC, et al. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 1996;220:171-6.
27. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
28. Wright HI, Gavaler JS, Van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-4.
29. Cattral MS, Krajden M, Wanless IR, Rezig M, Cameron R, Greig PD, et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996;61:1483-8.
30. Feray C, Samuel D, Gigou M, Reynes M, Bismuth H. Reduced incidence of recurrent and acquired infection by HCV after liver transplantation in patients receiving immunoglobulin (abstract). Hepatology 1994;20:131A.
31. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003;52:283-7.
32. Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988;2:132-5.
33. Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986;314:1418-23.
34. Halme L, Hockerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003;75:1853-8.
35. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-70.
36. Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, et al. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Nephrol Dial Transplant 2003;18:809-13.
37. Freeman R, Slifkin M, Ruthzer R, Mithoefer A, Angelis M, Rohrer R, et al. Intense CMV prophylexis reduces rejection in orthotopic liver transplantation. Am J Transpl 2001; 2(Suppl 3):199.
38. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma. in kidney and heart transplant recipients. Lancet 1993;342:1514-16.
39. Randhawa PS, Yousem SA, Paradis IL, Dauber JA, Griffith BP, Locker J. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lympho proliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 1989;92:177-85.
40. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lympho-proliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-52.
41. Green M. Preemptive therapy: Epstein-Barr virus. Transplant Proc 1996;28(6Suppl 2):5-6.
42. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997;37:45-51.
43. Simonds RJ. HIV transmission by organ and tissue transplantation. AIDS 1993;7 (Suppl2):S35-S38.
44. Centers for Disease Control and Prevention. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Morb Mortal Wkly Rep 1994;43:1-17.
45. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature 1981;294:268-71.
46. Remesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV-I by kidney transplant. Transfusion 2000;40:1421-2.
47. Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of human herpes virus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998;339:1358-63.
48. Milliancourt C, Barete S, Marcelin AG, Mouquet C, Dupin N, Frances C, et al. Human herpesvirus-8 seroconversions after renal transplantation. Transplantation 2001;72:1319-20.
49. Leads from the MMWR. Update: Creutzfeldt-Jakob disease in a patient receiving a cadaveric dura mater graft. JAMA 1987;258:309-10.
50. Firlit CF, Jonasson O, Kahan BD, Bergan JJ. Reye syndrome cadaveric kidneys: Their use in human transplantation. Arch Surg 1974;109:797.
51. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196-203.
52. Doig RL, Boyd PJ, Eykyn S. Staphylococcus aureus transmitted in transplanted kidneys. Lancet 1975;2:243-5.
53. Gottesdiener KM. Transplanted infections: Donor-to-host transmission with the allograft. Ann Intern Med 1989;110:1001-16.
54. Weber TR, Freier DT, Turcotte JG. Transplantation of infected kidneys: Clinical and experimental results. Transplantation 1979;27:63-5.
55. Nelson PW, Delmonico FL, Tolkoff-Rubin NE, Cosimi AB, Fang LS, Russell PS, et al. Unsuspected donor Pseudomonas infection causing arterial disruption after renal transplantation. Transplantation 1984;37:313-14.
56. Satoi S, Bramhall SR, Solomon M, Hastings M, Mayer AD, de Goyet JV, et al. The use of liver grafts from donors with bacterial meningitis. Transplantation 2001;72:1108-13.
57. Lopez-Navidad A, Domingo P, Caballero F, Gonzalez C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation 1997;64:365-8.
58. Paigi JM, Lopez-Navidad A, Lloveras J, Mir M, Orfila A, Quintana S, et al. Organ donors with adequately treated bacterial meningitis may be suitable for successful transplantation. Transplant Proc 2000;32:75-7.
59. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997;336:708-16.
60. Freeman RB, Giatras I, Falagas ME, Supran S, O'Connor K, Bradley J, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999;68:1107-11.
61. Lammermeier DE, Sweeney MS, Haupt HE, Radovancevic B, Duncan JM, Frazier OH. Use of potentially infected donor hearts for cardiac transplantation. Ann Thorac Surg 1990;50:222-5.
62. Little DM, Farrell JG, Cunningham PM, Hickey DP. Donor sepsis is not a contraindication to cadaveric organ donation. QJM 1997;90:641-2.
63. Caballero F, Lopez-Navidad A, Gomez M, Sola R. Successful transplantation of organs from a donor who died from acute cocaine intoxication. Clin Transplant 2003;17:89-92.
64. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998;27:1266-77.
65. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997;63:1278-86.
66. Gibel LJ, Sterling W, Hoy W, Harford A. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol 1987;138:1226-7.
67. Caballero F, Domingo P, Rabella N, Lopez-Navidad A. Successful transplantation of organs retrieved from a donor with syphilis. Transplantation 1998;65:598-9.
68. Ko WJ, Chu SH, Lee YH, Lee PH, Lee CJ, Chao SH, et al. Successful prevention of syphilis transmission from a multiple organ donor with serological evidence of syphilis. Transplant Proc 1998;30:3667-8.
69. Rose AG, Uys CJ, Novitsky D, Cooper DY, Barnard CN. Toxoplasmosis of donor and recipient hearts after heterotopic cardiac transplantation. Arch Pathol Lab Med 1983;107:368-73.
70. Hakim M, Wreghitt TG, English TA, Stovin PG, Cory-Pearce R, Wallwork J. Significance of donor transmitted disease in cardiac transplantation. J Heart Transplant 1985;4:302-6.
71. Mason JC, Ordelheide KS, Grames GM, Thrasher TV, Harris RD, Bui RH, et al. Toxoplasmosis in two renal transplant recipients from a single donor. Transplantation 1987;44:588-91.
72. Kusne S, Dummer JS, Ho M, Whiteside T, Rabin BS, Makowka L, et al. Self-limited Toxoplasma parasitemia after liver transplantation. Transplantation 1987;44:457-8.
73. Keogh A, Macdonald P, Richens D, Harvison A, Spratt P. Mini-dose trimethoprim with sulphamethoxazole prevents pneumocystis and toxoplasmosis infections after heart transplantation. Transplant Proc 1992;24:2263.
74. Ferraz AS, Figueiredo JF. Transmission of Chagas' disease through transplanted kidney: Occurrence of the acute form of the disease in two recipients from the same donor. Rev Inst Med Trop Sao Paulo 1993;35:461-3.
75. de Faria JB, Alves G. Transmission of Chagas' disease through cadaveric renal transplantation. Transplantation 1993;56:1583-4.
76. Fischer L, Sterneck M, Claus M, Costard-Jackle A, Fleischer B, Herbst H, et al. Transmission of malaria tertiana by multi-organ donation. Clin Transplant 1999;13:491-5.
77. Ciancio G, Burke G, Roth D, Zucker K, Tzakis A, Miller J. The significance of infections in donor organs. Transplant Immunol 1996;12:3.
78. Keating MR, Guerrero MA, Daly RC, Walker RC, Davies SF. Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. Chest 1996;109:1119-24.
79. Bonatti H, Konigsrainer A, Allerberger F, Riedmann B, Margreiter R, Steurer W. How to treat graft infection after pancreatic transplantation. Transplant Proc 1995;27:3045-7.